Aggressive/Intermediate Grade Non-Hodgkin’s Lymphoma

CAR Therapy Effective in Advanced Lymphoma (06-20-2016)

According to results of several presentations at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO), chimeric antigen receptor (CAR) therapies appear to have significant anti-cancer activity among patients with different types... Continue Reading

HIV-Positive Patients with Lymphoma Should No Longer be Excluded From Receiving Blood Stem Cell Transplants as Treatment (12-17-2014)

HIV-positive patients with lymphoma were previously excluded from receiving autologous blood stem cell transplants as treatment, because of concern that these patients’ compromised immune systems would have a higher risk of infection and poor graft... Continue Reading

Adding Revlimid to R-CHOP May Improve Outomes of Selected Patients with NHL (09-4-2014)

The results of a recently completed study reported in the Journal of Clinical Oncology indicate that the addition of Revlimid® (lenalidomide) to R-CHOP the standard treatment for non hodgkin lymphoma (NHL) can overcome the negative prognostic effect... Continue Reading

Anti-CD19 Chimeric Antigen Receptor (CAR) T Cells Reported to be Effective in Aggressive Non-Hodgkin’s Lymphoma at the National Cancer Institute (NCI) (09-3-2014)

SANTA MONICA, Calif., Aug. 25, 2014 (GLOBE NEWSWIRE) — Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, announced... Continue Reading

Lenalidomide Added to R-CHOP21 Therapy Shows High Response in Elderly, Untreated Large B-Cell Lymphoma Patients (05-28-2014)

Researchers reported in the journal The Lancet Oncology that the addition of lenalidomide to the standard R-CHOP21 regimen elicited a high response rate in elderly patients with untreated diffuse large B-cell lymphoma. In addition, the combination therapy... Continue Reading

Celiac Disease Associated with Higher Risk of Lymphoma (09-4-2013)

Individuals with celiac disease have an increased risk of lymphoma, particularly if they have a condition known as persistent villous atrophy, according to the results of a large cohort study published in the Annals of Internal Medicine.[1] Celiac disease... Continue Reading

Routine CT Scans May Not Be Necessary for Many Lymphoma Survivors (06-25-2013)

After treatment for diffuse large B cell lymphoma (DLBCL), only a small minority of patients have a relapse detected through routine surveillance CT scans alone, suggesting that routine scans have limited value for these patients. These results were presented... Continue Reading

Rituxan May Prevent Need for Radiation in Mediastinal B-Cell Lymphoma (05-31-2013)

A dose-adjusted, infusion approach to aggressive chemotherapy with Rituxan® (rituximab) may allow patients with primary mediastinal B-cell lymphoma to skip radiation, according to the results of a study published in the New England Journal of Medicine. Non-Hodgkin’s... Continue Reading

RIT Conditioning with Zevalin Prior to Autologous Transplantation Improves Overall Survival in Patients with DLCL (04-5-2013)

Radioimmunotherapy conditioning with Zevalin® (ibritumomab tiuxetan) prior to autologous stem cell transplantation in patients with diffuse large cell lymphoma offers a similar relapse incidence to total body irradiation, but has lower toxicity and improved... Continue Reading

Treanda Plus Rituxan is Not Inferior to R-CHOP and R-CVP for advanced NHL (04-2-2013)

The combination of Treanda® (bendamustine) and Rituxan® (rituximab) was found to be noninferior to the commonly used chemotherapy regimens R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) and R-CVP (rituximab plus cyclophosphamide,... Continue Reading

Next Page »